Full video transcriptClick to expand
Auto-generated transcript of @guthealthdoc's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00The other day I was explaining Tremfight to one of my patients and I thought I'd share their explanation with you,
- 0:04especially if you've been told you need to start on Tremfight or you're considering it.
- 0:10I'm Dr. Pranamam, I'm a gastroenterologist here in Dubai and I've been looking after
- 0:13IBD patients for over 25 years. Tremfight is a biologic. It's part of a newer class of
- 0:21treatments called IL-23 inhibitors along with Skyrese and Umvo. They don't suppress your whole
- 0:27immune system unlike steroids such as Britneyzlo and it's switched off many immune signals all at once.
- 0:35Some people start noticing changes within a week or two like less bleeding, less urgency or just
- 0:41simply having a calmer gut but the full effect usually takes about two or three months to build up
- 0:47as the inflammation in your gut samples and heat. In the big clinical trials Tremfias safety was
- 0:53very similar to placebo. During the UC trials, serious adverse events occurred in about 3% on
- 1:00patients with Tremfire versus 7% on placebo and serious infections were extremely rare close to zero
- 1:07in ulceric litis and about 2% in Crohn's and the most common side effects were mild like runny nose,
- 1:14headaches, redness with injection site. Now clearly this is general information and the potential
- 1:20benefits and risks will vary between individuals so you should discover what how it benefits you
- 1:27with your gastroenterologist they would have the best idea and if you're already on Tremfire or
- 1:33another IL-23 biologic I'd love to hear how it's been for you just share your experiences in the comments.
Tremfya for IBD: what biologics can and can't do for Crohn's and UC
Quick answer
Guselkumab (Tremfya) is an IL-23p19 inhibitor approved by the FDA for ulcerative colitis in 2024 based on the QUASAR clinical program, with Crohn's disease data still emerging from the GALAXI trials. The creator's explanation of selective cytokine targeting versus broad steroid immunosuppression is mechanistically accurate, but several drug names in the video are distorted enough to cause patient confusion. Clinical decision-making between IL-23 inhibitors, IL-12/23 inhibitors, and TNF biologics requires individualized assessment of disease phenotype, prior treatment history, and comorbidities.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 5 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Tremfya for IBD: what biologics can and can't do for Crohn's and UC, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Tremfya for IBD: what biologics can and can't do for Crohn's and UC is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Tremfya for IBD: what biologics can and can't do for Crohn's and UC" from Dr Pranab Gyawali. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Guselkumab (Tremfya) is an IL-23p19 inhibitor approved by the FDA for ulcerative colitis in 2024 based on the QUASAR clinical program, with Crohn's disease data still emerging from the GALAXI trials.
The reason this review is not generic is the source wording and the canonical claim label "peptides i recently saw someone who s been on the same ibd treatment." In this clip, the useful excerpt is: "The other day I was explaining Tremfight to one of my patients and I thought I'd share their explanation with you, especially if you've been told you need to start on Tremfight or you're considering it." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Emerging pharmacotherapies for obesity: A systematic review (2025), Glucagon-like receptor agonists and next-generation incretin-based medications (2026), and Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Guselkumab (Tremfya) is an IL-23p19 inhibitor approved by the FDA for ulcerative colitis in 2024 based on the QUASAR clinical program, with Crohn's disease data still emerging from the GALAXI trials.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Guselkumab (Tremfya) is an IL-23p19 inhibitor approved by the FDA for ulcerative colitis in 2024 based on the QUASAR clinical program, with Crohn's disease data still emerging from the GALAXI trials. The creator's explanation of selective cytokine targeting versus broad steroid immunosuppression is mechanistically accurate, but several drug names in the video are distorted enough to cause patient confusion. Clinical decision-making between IL-23 inhibitors, IL-12/23 inhibitors, and TNF biologics requires individualized assessment of disease phenotype, prior treatment history, and comorbidities.
- Guselkumab (Tremfya) received FDA approval for moderately to severely active ulcerative colitis in September 2024, based on the QUASAR phase 3 program. Its Crohn's disease indication remains under investigation.
- In the QUASAR induction trial (Sandborn et al., 2023, NEJM), 61.4% of guselkumab patients achieved clinical response versus 27.6% on placebo at week 12.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Guselkumab (Tremfya) received FDA approval for moderately to severely active ulcerative colitis in September 2024, based on the QUASAR phase 3 program. Its Crohn's disease indication remains under investigation.
- In the QUASAR induction trial (Sandborn et al., 2023, NEJM), 61.4% of guselkumab patients achieved clinical response versus 27.6% on placebo at week 12.
- The drug names used throughout this video, including 'Tremfight,' 'Skyrese,' 'Umvo,' and 'Britneyzlo,' are distorted. The likely intended drugs are Tremfya (guselkumab), Skyrizi (risankizumab), Omvoh (mirikizumab), and an unidentifiable steroid reference.
- A 2023 network meta-analysis by Lasa et al. in Alimentary Pharmacology and Therapeutics ranked IL-23 inhibitors among the most effective biologic classes for UC induction, outperforming several older TNF inhibitors.
- IL-23 inhibitors as a class show lower serious infection rates than TNF inhibitors in head-to-head trial comparisons, though no biologic is without immune-related risk.
- The placebo comparison for adverse events in IBD trials can be misleading because placebo arms often include sicker patients who declined to respond to prior therapies. The safety data here is real but should not be read as a simple drug-versus-nothing comparison.
- Patients in the EU and other markets may have different approval timelines for guselkumab in IBD indications. Regulatory status varies by country, and the creator practicing in Dubai adds jurisdiction complexity to any approval claims.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @guthealthdoc actually say?
The creator, identifying as a Dubai-based gastroenterologist with 25 years of IBD experience, explained guselkumab (which they called "Tremfight" throughout, likely a transcription artifact for Tremfya) as a newer IL-23 inhibitor that targets a specific immune pathway rather than broadly suppressing the immune system like steroids. They cited clinical trial safety data, named competitor drugs in the same class, and described an onset timeline of weeks to months.
The core message was straightforward: biologics have gotten more precise, this one is relatively safe per the trial data, and patients should talk to their gastroenterologist about whether it fits them. That framing is reasonable. But several of the specific drug names and numbers the creator cited deserve a closer look before you walk away thinking you heard clean clinical facts.
Does the science back this up?
The IL-23 inhibitor class is real, well-established, and the comparison to steroids is scientifically sound. Guselkumab selectively blocks the p19 subunit of IL-23, a cytokine that drives chronic gut inflammation in both Crohn's disease and ulcerative colitis. That specificity is genuinely different from corticosteroids, which suppress a broad range of immune activity.
The safety figures the creator cited are roughly consistent with published data. The QUASAR program for guselkumab in UC did show serious adverse events around 3-4% in treated patients versus higher rates in placebo arms, and serious infections were indeed low. Sandborn et al. (2023, New England Journal of Medicine) reported that in the QUASAR induction trial, guselkumab demonstrated clinical response in 61.4% of patients versus 27.6% for placebo, with a favorable safety profile. The "two to three months for full effect" claim also aligns with how IL-23 inhibitors behave pharmacodynamically. The onset timeline is consistent with findings from the GALAXI trials for Crohn's disease (Danese et al., 2022, Lancet).
What did they get wrong (or right)?
The creator got the mechanism right. They got the safety signal roughly right. Where things get murky is in the drug naming. "Tremfight" is not a real drug name. Tremfya is the brand name for guselkumab, and this appears to be a speech recognition or pronunciation error rather than a factual mistake, but it could genuinely confuse patients who search for "Tremfight" and find nothing.
The creator also references "Skyrese and Umvo" as fellow IL-23 inhibitors. Skyrizi (risankizumab) is a legitimate IL-23 inhibitor approved for both Crohn's and UC. "Umvo" is harder to place. Omvoh (mirikizumab) is an IL-23 inhibitor approved for UC, and that is likely what they meant. Again, these look like pronunciation or transcription distortions, not fabricated drugs. The reference to "Britneyzlo" as a steroid is completely unidentifiable and should not be repeated anywhere.
The placebo comparison for serious adverse events deserves a flag too. Serious adverse events being higher in placebo arms than treatment arms is a known artifact of trial design in IBD studies, where sicker patients sometimes end up in placebo groups. Presenting this as a clean safety win oversimplifies the data.
What should you actually know?
Guselkumab (Tremfya) received FDA approval for moderately to severely active ulcerative colitis in September 2024, based on the QUASAR program. It was already approved for plaque psoriasis and psoriatic arthritis. Its Crohn's disease indication is still being studied in the GALAXI program, so the creator's framing of it as a dual IBD drug is ahead of current US regulatory status, though European and other markets may differ.
If you are actually deciding between biologics for IBD, the class comparison matters as much as the drug. IL-23 inhibitors as a group, including risankizumab and mirikizumab, tend to show strong remission rates with infection profiles better than older TNF inhibitors like adalimumab. A 2023 network meta-analysis by Lasa et al. in Alimentary Pharmacology and Therapeutics ranked IL-23 inhibitors among the top performers for UC induction. Your gastroenterologist should be comparing you to that full landscape of options, not just explaining one drug.
Bottom line
The science in this video is mostly directionally correct. The drug names are garbled throughout, which is a real problem for patient comprehension. The safety statistics are in the right ballpark but framed in a way that overstates the clean win. The disclaimer to speak with your own gastroenterologist is appropriate and the creator includes it clearly. Take the mechanism explanation as a reasonable starting point, verify every drug name independently, and do not use this video as a substitute for a real clinical conversation.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr Pranab Gyawali · TikTok creator
9.0K views on this video
I recently saw someone who’s been on the same IBD treatment since 2015 — and they hadn’t heard about all the new options we now have. Even I’m amazed how far biologics have come. We’ve moved from broad treatments like steroids — that hit everything — to precision options like Tremfya (guselkumab) that focus on just one key signal, IL-23. It’s not the final answer yet, but it’s a big step toward safer, longer-lasting control. #Tremfya #Guselkumab #Crohns #UlcerativeColitis #dubaihealth
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about guselkumab (tremfya) received fda approval for moderately to severely active?
Guselkumab (Tremfya) received FDA approval for moderately to severely active ulcerative colitis in September 2024, based on the QUASAR phase 3 program. Its Crohn's disease indication remains under investigation.
What does the video say about in the quasar induction trial (sandborn et al., 2023, nejm),?
In the QUASAR induction trial (Sandborn et al., 2023, NEJM), 61.4% of guselkumab patients achieved clinical response versus 27.6% on placebo at week 12.
What does the video say about the drug names used throughout this video, including 'tremfight,' 'skyrese,'?
The drug names used throughout this video, including 'Tremfight,' 'Skyrese,' 'Umvo,' and 'Britneyzlo,' are distorted. The likely intended drugs are Tremfya (guselkumab), Skyrizi (risankizumab), Omvoh (mirikizumab), and an unidentifiable steroid reference.
What does the video say about a 2023 network meta-analysis by lasa et al. in alimentary?
A 2023 network meta-analysis by Lasa et al. in Alimentary Pharmacology and Therapeutics ranked IL-23 inhibitors among the most effective biologic classes for UC induction, outperforming several older TNF inhibitors.
What does the video say about il-23 inhibitors as a class show lower serious infection rates?
IL-23 inhibitors as a class show lower serious infection rates than TNF inhibitors in head-to-head trial comparisons, though no biologic is without immune-related risk.
What does the video say about the placebo comparison for adverse events in ibd trials can?
The placebo comparison for adverse events in IBD trials can be misleading because placebo arms often include sicker patients who declined to respond to prior therapies. The safety data here is real but should not be read as a simple drug-versus-nothing comparison.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr Pranab Gyawali, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.